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ABSTRACT
Introduction Breast cancer has become a chronic 
disease due to survival improvement and the need to 
monitor the side effects of treatment and the disease 
itself. The aim of the SURBCAN study is to describe 
comorbidity, healthcare services use and adherence 
to preventive recommendations in long- term breast 
cancer survivors and to compare them with those in 
women without this diagnosis in order to improve and 
adapt the care response to this group of survivors.
Methods and analysis Population- based 
retrospective cohort study using real- world data from 
cancer registries and linked electronic medical records 
in five Spanish regions. Long- term breast cancer 
survivors diagnosed between 2000 and 2006 will be 
identified and matched by age and administrative 
health area with women without this diagnosis. 
Sociodemographic and clinical variables including 
comorbidities and variables on the use of health 
services between 2012 and 2016 will be obtained 
from databases in primary and hospital care. Health 
services use will be assessed through the annual 
number of visits to primary care professionals and to 
specialists and through annual imaging and laboratory 
tests. Factors associated with healthcare utilisation 
and comorbidities will be analysed using multilevel 
logistic regression models. Recruitment started in 
December 2018.
Ethics and dissemination This study was approved 
by the Ethics Committee of Parc de Salut Mar. The 
results of the study will be published in a peer- 
reviewed journal and will be presented at national 
and international scientific conferences and at patient 
associations.
Trial registration number This protocol is registered 
in Clinical  Trials. gov (identifier: NCT03846999).
INTRODUCTION
The term long- term breast cancer survivor 
(BCS) defines women surviving at least 5 years 
free from cancer recurrence or new primary 
cancer.1 The number of BCS is gradually 
increasing, particularly in Western countries, 
and trends suggest their number will continue 
to increase due to improvements in breast 
cancer screening, advances in diagnosis and 
Strengths and limitations of this study
 ► To our knowledge, this is the first study focusing 
on long- term breast cancer survivors and aiming 
to assess survivors’ use of health services ac-
cording to their health status and comorbidities. It 
will also assess adherence to the main preventive 
recommendations.
 ► In addition, this study is based on real- world data, 
which allows patient behaviour to be tracked in 
terms of health services use according to their 
health status and socioeconomic situation during 
the 5- year follow- up.
 ► The study design includes a group of women who 
have survived at least 5 years since the breast can-
cer diagnosis and a second group of women without 
a history of breast cancer which allows to compare 
the healthcare use between both groups.
 ► A limitation of the study may be the differences in 
the availability and quality of the data in the partic-
ipating regions.
 ► Our findings will be valuable to improve current 
practices, estimate the resources needed and to 
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treatment and greater life expectancy.2 3 Recent data from 
the National Cancer Institute show that in 2019, when all 
stages of cancer are combined, the overall 5- year relative 
breast cancer survival rate is 90%.4–6 In Europe, the age- 
standardised 5- year survival rates are around 87% in the 
Nordic countries and 83.7% in Spain.7 8 This increase has 
led to a growing need by clinicians and researchers to 
study and assess the needs and patient- centred outcomes 
of long- term BCS.3 9
Research on healthcare services use and comorbidi-
ties in long- term BCS has been established as a priority 
by The National Cancer Institute of the USA, which has 
included the assessment of the needs and challenges of 
a growing population of cancer survivors among their 
six priorities for cancer- related public health research.10 
Cancer survivors’ follow- up is a phase of cancer care and 
includes surveillance, symptom control, treatment of 
comorbidities and complications, psychosocial needs and 
care coordination mechanisms. Several European organ-
isations, such as the National Health Service in the UK, 
the European Breast Cancer Coalition and the Spanish 
Medical Oncology Society (SEOM), have published 
recent recommendations regarding the characteristics of 
follow- up and recommendations on the tests that should 
be provided to this group of women. All of them highlight 
the importance of providing a collaborative and coordi-
nated follow- up shared between primary and specialised 
care.11–13 These guidelines also include recommendations 
on the assessment and management of comorbidities in 
long- term BCS.
Comorbidities associated with both the side effects of 
breast cancer treatment and with ageing have been widely 
described, although research has focused on survivors 
overall rather than on long- term BCS specifically.14–20 In 
2016, the International Consortium for Health Outcomes 
Measurement (ICHOM) described the main comorbid-
ities associated with breast cancer, which include a wide 
range of patient- related outcomes as well as clinical 
health disorders such as arthralgia, anxiety and cardiovas-
cular disorders.21 Bradshaw et al22 showed that long- term 
BCS are at higher risk for cardiovascular disease- related 
mortality than women without breast cancer. Moreover, 
30% of BCS reported symptoms of mental distress during 
the survival period23 and around 30% had hypertension 
and hypercholesterolemia.24 25
In contrast, very few studies have so far evaluated 
health services use and adherence to recommendations 
for long- term BCS. The factors reported to be associated 
with lower adherence include higher age at diagnosis, the 
presence of comorbidities, and a low educational level,26 27 
but there is little information on long- term survivors.28–30 
Another important factor that can also affect adherence 
is which recommendations are made to patients by health 
professionals and how they are delivered.
Answers to public health questions can be provided by 
population cohorts based on real- world data from elec-
tronic medical records (EMR) and clinical- administrative 
data and take into account participants’ global context. 
Such studies are the preferred options in research in 
health services.31 32 Nevertheless, to our knowledge, 
currently, there is no cohort of long- term BCS using EMR 
either in Spain or elsewhere in southern Europe.33 34
In 2016 the SURBCAN study (SUrvival Breast CANcer 
Cohort) was initiated by the REDISSEC (Spanish acronym 
for: Red de Investigación en Servicios de Salud en Enferme-
dades Crónicas (Health Services Research on Chronic 
Patients Network)). This project combines the experi-
ence of expert groups in longitudinal analysis, health 
services assessment, analysis of comorbidities and chronic 
diseases belonging to the REDISSEC network. REDISSEC 
conducts health services research projects to provide 
solid evidence of best policies, practices and organisa-
tional models to address chronicity.35
The SURBCAN cohort includes long- term BCS as well 
as controls with no a history of breast cancer, matched by 
age and administrative health area treated in the Spanish 
National Health System (SNS), in order to characterise 
the care provided by the SNS to long- term BCS and to 
compare their health outcomes. The SNS is based on 
the right of every citizen to health protection, public 
financing and provision of services that ensure the quality 
of care, among other rights. The SNS is decentralised in 
autonomous communities (AC). The decentralisation 
process, finalised in 2001, aimed to adapt health manage-
ment to the territorial and demographic characteristics of 
each AC. Furthermore, the Ministry of Health created a 
Health Information System within the SNS to ensure the 
availability of information and communication between 
the government and the AC.
METHODS AND ANALYSIS
Primary objective
The main aim of this cohort is to describe comorbidity, 
healthcare services use and adherence to preventive 
recommendations among women surviving breast cancer 
for 5 years or more.
Design and setting
The SURBCAN study is an observational population- 
based retrospective cohort study that includes long- 
term BCS and a control group of women without history 
of breast cancer from five Spanish areas: Hospital del 
Mar and SIDIAP (Information System for Primary Care 
Research in Catalonia), Hospital Costa del Sol in Anda-
lusia, Hospital 12 de Octubre and Primary Care in Madrid, 
Navarre and the EpiChron Cohort in Aragón. This study 
protocol was developed on the basis of the Strengthening 
the Reporting of Observational Studies in Epidemiology 
checklist statement for cohort studies (online supplemen-
tary material 1).36 37 The recruitment started at the end of 
2018 after having obtained the ethical approval.
Study population
All women≥18 years old with a diagnosis of incident 
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least 5 years after diagnosis will be identified in each 
of the subcohorts participating in this study. To ensure 
a minimum 5- year survival period, all included women 
must be alive at the beginning of the survival period (1 
January 2012). Women with unknown date of diagnosis 
will be excluded.
In addition, BCS will be only included if they will have 
attended at least one visit to primary care health services 
during the follow- up period (01 January 2012 to 31 
December 2016). The SURBCAN cohort also includes 
a control group composed of selected women without a 
breast cancer diagnosis, matched by age and administra-
tive health area, with BCS. Women in the control group 
will be identified through the primary care registries of 
each participating area. All data contained in the cohort 
will be anonymised. Data collection in the participating 
centres is described in figure 1.
Information source and data collection
The SURBCAN cohort is based on real- world data 
from EMR (includes primary and hospital care) and 
from tumour registries (hospital and population- based 
registries). The variables collected in the SURBCAN 
cohort are drawn from patients’ routine contacts with the 
taxpayer- funded health system in Spain (figure 2). Socio-
demographic and lifestyle information, pharmaceutical 
prescriptions, comorbidities and all visits (including emer-
gency visits and hospital admissions) and tests performed 
in both primary and specialised care will be obtained 
through databases from the SIDIAP, the Health Service of 
Madrid, the Health Service of Andalusia, Osansunbidea 
(Navarre Health Service) and the EpiChron Cohort 
from Aragón for both BCS and controls. Information 
on tumour characteristics and cancer treatment will be 
obtained from hospital and regional tumour registries for 
BCS. Sociodemographic and lifestyle information will be 
obtained in the first contact with the health system in the 
follow- up period (1 January 2012 to 31 December 2016) 
for each woman. Information is obtained on each visit to 
primary, specialised and hospital care (date of visit, type 
of visit and professional visited), all diagnostic tests (date 
and type of test) and referrals for the whole follow- up 
period in order to obtain the history of contacts to health-
care services. Comorbidities and drug prescriptions will 
be extracted at the beginning (first contact) and at the 
end (last contact) of follow- up.
To analyse comorbidities, the original diagnoses from 
the International Disease Classification (IDC-9, IDC-10) 
and from the International Classification of Primary 
Care will be coded according to the expanded diagnosis 
clusters (EDCs) using the list of 114 chronic EDCs devel-
oped by Salisbury. This list groups together diseases that 
describe similar or related conditions and is internation-
ally used to define comorbidity and multimorbidity.38 39 
In addition, comorbidities derived from breast cancer 
as defined by ICHOM are also included. Diagnoses will 
be obtained from the Primary Care Clinical Database 
(PCCD) of each region included in the study.40
Drugs will be coded using the International Anatomical 
Therapeutic Chemical classification for medicines, main-
tained by the WHO. These women will be included in the 
pertinent analysis until the date of withdrawal.
Sample size calculation
The sample size is estimated on the comparison of two 
means of the number of visits to hospital outpatient 
consultations per woman, matched per case and two 
controls. A female BCS has an average of 18.4 consulta-
tions (preliminary data from Hospital del Mar in 2012) 
and we aimed to detect a difference with women without 
breast cancer of at least three consultations. Assuming a 
SD of 25, a significance level of 5% and a statistical power 
of 80%, we needed a sample of 1619 cases and 3238 
controls. The Hospital del Mar tumour registry, which 
covers a population of 300 000 inhabitants, contained 
data on 1676 women with breast cancer diagnosed and 
treated in the same hospital between 2005 and 2010 and 
who survived a minimum of 5 years after diagnosis.
Given that this sample already guaranteed the minimum 
number of cases for the study, the inclusion of cases from 
Figure 1 Flowchart of the SURBCAN study. BCS, breast 
cancer survivor; SNS, Sistema nacional de salud (National 
Health Service); EMR, electronic medical record.
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the rest of the participating areas will allow all the study 
questions set to be answered and the necessary adjust-
ments to be made.
Statistical analysis
Demographic and clinical characteristics of the patients 
will be described, by group (BCS/control group) and 
by area, using mean and SD, median and interquartile 
ranges, or frequencies with proportions, depending on 
the nature of the variables. The pattern of health services 
utilisation will be described through rates per 100 person- 
years. Differences in demographic and clinical variables 
between BCS and the control group will be assessed by 
parametric and non- parametric tests, such as the Student’s 
t- test, or the Mann- Whitney U- test, whereas differences 
in utilisation rates will be assessed using incidence rate 
ratios, with 95% CIs from the exactci package in R.
For the analyses of comorbidities, diagnoses associated 
with chronic diseases will be identified to differentiate 
them from acute diagnoses. The prevalence of comor-
bidities will be compared between groups and according 
to certain sociodemographic variables (age group, sub- 
cohorts, nationality, administrative health area and 
deprivation index) using the χ2 test, the trend for propor-
tions test or other parametric and non- parametric tests, 
depending on the nature of the variables. The presence 
of specific comorbidities by group (and also according to 
the characteristics of the primary tumour and the treat-
ment received by the BCS group) will also be assessed 
with logistic regression models, to account for possible 
confounding variables, which will provide ORs with 95% 
CIs. The incidence of new comorbidities in the follow- up 
will also be modelled with the same methodology.
For the analysis of health services utilisation, gener-
alised linear models that may have different specifications 
depending on the distribution of the dependent variables 
(number of visits, number of hospital admissions, etc) will 
be fitted. For rare events, such as the number of hospital 
admissions, count models (Poisson, negative binomial 
or zero- inflated models) will be fitted, including group 
as exposure, exposure- time (total follow- up time, taking 
into account possible censorship such as death or loss to 
follow- up due to other causes) as offset and clinical and 
demographic characteristics as potentially confounding 
variables. For more frequent data, such as the number 
of visits, linear models will be fitted, with log- transformed 
data if necessary and the same covariates as for count data. 
Complementarily, a sensitivity analysis will be performed 
to determine which factors have the strongest influence 
on the variation in resource consumption.
All analyses, both crude and adjusted, will be stratified 
by BCS and by women with no history of breast cancer 
in order to study the distribution of confounders in the 
sample. As this is a matched cohort by age and adminis-
trative health area, a similar distribution of sociodemo-
graphic is expected.
Additionally, the level of adherence to the American 
Society of Clinical Oncology and SEOM breast cancer 
follow- up guidelines during the study period according 
to tumour characteristics and time from diagnosis (5–10 
years and 10 or more years) will be analysed using logistic 
regression, considering as dependent variables whether 
or not each recommendation was fulfilled.
Regarding missing data, women with unknown infor-
mation in the variables of interest will be excluded from 
each analysis. Each analysis will include in its description 
the number of missing and it will be decided to impute or 
not according to this number. However, sensitivity anal-
yses will be carried out to study the effect of missing data.
Quality assurance
The main challenge for the construction of a common and 
systematic clinical database is the need to bring together 
the existing decentralised information in the different 
medical records of the AC.39 All the team members and 
the data managers in charge of each subcohort will be are 
provided with a handbook drafted by the main research-
er’s team, which includes the overall description of the 
project, the team members and their contacts, the struc-
ture and methodology, and a detailed definition of all 
the variables included in the project. In addition, they 
will be provided with a quality control protocol for the 
SURBCAN database, which defines the accepted values 
for each variable, the range of possible values, and logical 
validation rules for the entire study population. Each 
subcohort will carry out case identification in their area 
and anonymisation following the steps described in the 
protocols.
The project has a web platform that works as a data 
deployment web. It has private access with a password. The 
data manager of each subcohort will upload data through 
this platform. By means of error detection software, the 
platform identifies the mistakes or inconsistencies in the 
uploaded data compared with specifications in the quality 
control protocol, so that data managers can correct and 
ensure data quality and homogeneity between the subco-
horts. Once all the data have been uploaded, the entire 
database will be validated by the main researcher’s team, 
who will also merge the databases, ensuring that the final 
database follows standards of good practice. During that 
process, a monthly online conference will be held to 
review the ongoing process and supervise the coordina-
tion of the study.
Patient and public involvement
The purpose of this study derives from previous research 
from our research group where the need arose to study 
the health needs of long- term BCSs and their relationship 
with health services. In previous studies, we have been in 
contact with patient associations as we believe it is essen-
tial to include their vision and current opinions.
Although patients and the public were neither involved 
in developing the hypothesis, the specific aims or the 
research question, nor were they involved in developing 
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results and conclusions will be discussed with members of 
patient with breast cancer associations in Spain.
DISCUSSION
The SURBCAN study provides a novel approach to 
describe comorbidity patterns and to assess healthcare 
services use based on real- world data and focused on 
long- term BCS.
The analysis of the data provided by this study will be 
used to assess the peculiarities of the care provided to 
long- term BCS in the Spanish National Health Service of 
Spain. The results of this study will allow estimation of 
the type of healthcare used by these women according 
to their comorbidities and/or level of risk, and their 
resource consumption compared with that of women 
without a history of breast cancer.
The conclusions and outcomes of this study will be 
useful for multiple stakeholders, including decision- 
makers, healthcare providers, medical organisations and 
patients to guide their decisions and to understand the 
most appropriate care for each BCS. This will be valu-
able information to improve current practices and health 
outcomes, to estimate the resources needed to deal with 
the increase in BCS in coming years and to assess adher-
ence to follow- up recommendations.
Strengths and weaknesses
The main strength of the SURBCAN study is that it 
is based on real- world data, which enables us to track 
patient behaviour regarding health services according 
to their health status and socioeconomic situation. Real- 
world data were obtained through EMR databases that 
include all the information from all levels of care of 
the Spanish health system: primary care, hospital care, 
specialised care, emergency room visits and consumption 
of resources, such as diagnostic and laboratory tests, as 
well as drug prescriptions.
EMR were created with a clear healthcare purpose and 
provide large sample sizes, broad representativeness of 
participants, minimisation of memory bias and an almost 
complete medical history including comorbidity informa-
tion. EMR allow chronic processes to be analysed from a 
multicausal approach as they include data from diverse 
sources. The quality of these databases has also been vali-
dated for the study of various chronic diseases.41 42
However, the availability of data can differ in each 
subcohort, since although all of them are within the 
framework of the Spanish National Health Service, each 
region has a different health service organisation and 
management models. For instance, date of diagnosis of 
comorbidities present at the first contact will not be avail-
able in all five regions given that EMR started in different 
years: in Hospital del Mar–SIDIAP the EMR started in 
2005, in Hospital Costa del Sol in 2007, in Hospital 12 
de Octubre–Primary care Service of Madrid in 2003, in 
Navarre the EMR of Primary Care started in 2004 and the 
EMR of specialised care in 2007 and in Aragón the EMR 
started in 2006. Detailed information regarding tumour 
characteristics and cancer treatment may not be fully 
available. To remedy the lack of information, depending 
on the number of missing, specific statistical analyses will 
be carried out. However, it is important to note that the 
methodology of real- world data analysis includes a less 
conservative treatment of unknown data. This translates 
into analysing the data as objectively as possible in order 
to understand the reality of the health system.
ETHICS AND DISSEMINATION
This project will be carried out in accordance with the 
basic principles of protection of human rights and dignity, 
as stated in the Declaration of Helsinki and in accor-
dance with the regulations in force. The Hospital del Mar 
Medical Research Institute, as the coordinating centre, 
obtained approval from its ethics committee. This study 
was approved by the Ethics Committee of Parc de Salut 
Mar (Catalonia), the Clinical Research Ethics Committee 
of the Government of Navarre, the Ethics Committee of 
the Jordi Gol University Institute for Research in Primary 
Care (Catalonia), the Ethics Committee of the Costa del 
Sol Health Agency (Andalusia), the Central Research 
Commission of the Community of Madrid and the Ethics 
Committee of Aragón.
All information obtained will be treated confiden-
tially and anonymously, in compliance with Organic Law 
3/2018 of 6 December. The usual care and attendance 
of the study population were unaffected and there were 
no changes or actions on treatments or visits, or collec-
tion or analysis of biological samples. Informed consent 
from patients was not necessary as the SURBCAN study 
is a retrospective observational project that only includes 
anonymised data from clinical and administrative data-
bases. The findings of this study will be published in a 
peer- reviewed journal and presented at national and 
international scientific conferences in order to dissem-
inate the results to academic, health professional and 
patient associations. The results will be available on our 
website to participants and to a wider public at the time 
of publication.
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